1[1]Yamaguchi K, Chijiwa K, Shimizu S et al. Comparison of endoscopic retrograde and magnetic resonance cholangiopancreatography in the surgical diagnosis of pancreatic diseasesl. Am J Surg,1998, 175(3) :203 - 208.
2[2]Nakaizumi A, Uehara H, Iishi H et al. Endoscopic ultrasonography in diagnosis and staging of pancreatic cancer. Dig Dis Sci,1995, 40(3) :696 - 700.
3[4]Uehara H, Nakaizumi A, Tatsuta M, et al. Diagnosis of carcinoma in situ of the pancreas by peroral pancreatoscopy and pancreatoscopiccytology. Cancer, 1997, 79(3):454-461.
4[5]Bares R, Klever P, Hauptmann S, et al. F- 18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology, 1994,192(1):79-86.
5[6]Friess H, Buchler M, Auerbach B, et al. CA 494 - a new tumor marker for the diagnosis of pancreatic cancer. Int J Cancer,1993, 53(5):759 -763.
6[7]Haglund C Lundin J, Kuusela P, et al. CA242, a new tumor marker for pancreatic cancer: a comparison with CA 19- 9, CA50 and CEA. Br J Cancer, 1994, 70(3) :487- 492.
7[8]Yiannakou JY, Newland P, Calder F, et al. Prospective study of CAM 17. 1/WGA mucin assay for serological diagnosis of pancreatic cancer. Lancet, 1997, 349(9049):389-392.
8[9]Ding X, Flatt PR, Permert J, et al. Pancreatic cancer cells selectively stimulate islet beta cells to secrete amylin.Gastroenterology, 1998, 114(1 ): 130 - 138.
9[10]Wakabayashi T, Sawabu N, Watanabe H, et al. Detection of K- ras point mutation at codon 12 in pure pancreatic juice collected 3 years and 6months before the clinical diagnosis of pancreatic cancer. Am - J - Gastroenterol, 1996, 91(9): 1848- 1851
5Jemal A,Murray T,Ward E,et al. Cancer statistics[J].2005,CA Cancer J Clin,2005,55 : 10-30.
6Niederau C,Grendell JH. Diagnosis of pancreatic cancer. Ima ging studies and tumor markers[J]. Pancreas, 1992,7(10):66 -86.
7DiMagno EP,Reber HA,Tempuro MA. AGA technical review on epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association[J]. Gastroenterology, 1999,117 : 1464-1484.
8Pasanen PA, Eskelinen M, Partanen K, et at. Receiver operating characteristic (ROC) curve analysis of the tumour markers CEA,CA50 and CA242 in pancreatic cancer,results from a prospective study [J].Br J Cancer, 1993.67(4).852- 855.
9Ozkan H, Kaya M, Cengiz A. Comparison of tumor marker CA242 with CA19 9 and carcinoernbryonic antigen (CEA) in pancreatic cancer [J]. Hepatogastroenterology, 2003,50 ( 53 ) :1669 -1674.
